Heron Therapeutics (FRA:AXD2) Pretax Margin %: -23.37% (As of Mar. 2026)


FRA:AXD2 Heron Therapeutics Inc FRA:AXD2
49 GF Score
Price €0.38
GF Value €1.40
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Heron Therapeutics Pretax Margin %?

Heron Therapeutics FRA:AXD2 +5.14% 49 Pretax Margin % is -23.37% as of Mar. 2026. GuruFocus rates FRA:AXD2 with a GF Score™ of 49/100 and a GF Value™ of €1.40 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 946 Biotechnology companies, Heron Therapeutics ranks better than 63.32% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Heron Therapeutics's Pre-Tax Income for the three months ended in Mar. 2026 was €-7.0 Mil. Heron Therapeutics's Revenue for the three months ended in Mar. 2026 was €30.0 Mil. Therefore, Heron Therapeutics's pretax margin for the quarter that ended in Mar. 2026 was -23.37%.

The historical rank and industry rank for Heron Therapeutics's Pretax Margin % or its related term are showing as below:

FRA:AXD2' s Pretax Margin % Range Over the Past 10 Years
Min: -13537.37   Med: -199.95   Max: -9.41
Current: -20.53


FRA:AXD2's Pretax Margin % is ranked better than
63.32% of 946 companies
in the Biotechnology industry
Industry Median: -90.5 vs FRA:AXD2: -20.53

Heron Therapeutics  (FRA:AXD2) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Heron Therapeutics Pretax Margin % Related Terms


Heron Therapeutics Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Heron Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heron Therapeutics Pretax Margin % Chart

Heron Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -255.58 -169.06 -87.02 -9.41 -13.04

Heron Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.77 -6.40 -45.78 -7.28 -23.37

FRA:AXD2 vs PLYX, ORMP, SPRO: Pretax Margin % Comparison

For the Biotechnology subindustry, Heron Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heron Therapeutics Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heron Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Heron Therapeutics's Pretax Margin % falls into.


FRA:AXD2
49GF Score
Heron Therapeutics Inc FRA:AXD2
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heron Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Heron Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-17.247/132.288
=-13.04 %

Heron Therapeutics's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-7.016/30.025
=-23.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of -23.37% mean?
Heron Therapeutics (FRA:AXD2) has a Pretax Margin % of -23.37% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Heron Therapeutics and its competitors. According to the industry distribution chart, Heron Therapeutics ranks #347 out of 946 companies in the Biotechnology industry, placing it in the top 36.7%.
Is Heron Therapeutics' Pretax Margin % too high?
Heron Therapeutics' current Pretax Margin % is -23.37%. Based on the distribution chart, Heron Therapeutics ranks #347 out of 946 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Heron Therapeutics has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Heron Therapeutics' Pretax Margin % compare to PLYX and ORMP?
According to the Biotechnology industry distribution chart, Heron Therapeutics ranks #347 out of 946 companies for Pretax Margin %. This puts Heron Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Heron Therapeutics and its competitors. Heron Therapeutics's current Pretax Margin % is -23.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heron Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Heron Therapeutics (FRA:AXD2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.40, compared to a current price of €0.38 — trading 73.1% below its estimated fair value. The current Pretax Margin % is -23.37%. Heron Therapeutics' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Heron Therapeutics (FRA:AXD2), the current Pretax Margin % is -23.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Heron Therapeutics (FRA:AXD2) Overvalued in 2026?

Based on GuruFocus' analysis, Heron Therapeutics stock appears to be undervalued. The current stock price of €0.38 is trading 73.1% below its estimated GF Value™ of €1.40. GuruFocus considers Heron Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:AXD2:

  • Pretax Margin %: -23.37%
  • GF Value™: €1.40 vs. price of €0.38 (73.1% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the FRA:AXD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Heron Therapeutics Business Description

Other Exchanges HRTX:USA0J4V:UKAXD2:Germany
Address 100 Regency Forect Drive, Suite 300, Cary, NC, USA, 27518
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
49GF Score

Get the complete analysis for FRA:AXD2

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.38
Price
€1.40
GF Value